STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated page for Bristol-Myers Squibb Co. news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co. stock.

Bristol-Myers Squibb Co. (BMY) is a renowned American multinational pharmaceutical company headquartered in New York City. As one of the largest pharmaceutical companies globally, Bristol-Myers Squibb (BMS) consistently ranks on the Fortune 500 list. In fiscal 2022, the company achieved total revenue of $46.2 billion.

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs across various therapeutic areas, including cardiovascular, cancer, and immune disorders. A significant area of focus for BMS is immuno-oncology, where it has established itself as a leader in drug development. Approximately 70% of BMS's total sales are derived from the U.S. market, reflecting its higher dependence on this region compared to its peers.

Recent achievements and collaborations highlight BMS's commitment to innovation and partnerships. On May 22, 2024, BMS joined NeoPhore Limited's oversubscribed Series B extension round. This additional investment will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (MMR) pathway in cancer, and further advance its pre-clinical studies. NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.

Another noteworthy collaboration was announced on June 5, 2024, with I-Mab, a U.S.-based global biotech company. This partnership will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody, with BMS's immune checkpoint inhibitor, nivolumab, and chemotherapy. The study, a multi-national Phase 1, will focus on advanced Claudin 18.2-positive gastric and esophageal cancers. BMS will supply nivolumab, which is designed to enhance T-cell function and improve anti-tumor responses.

Additionally, on June 5, 2024, Envisagenics, an AI-driven biotechnology company, announced a Series B fundraising round with participation from BMS. This funding will be utilized to further develop Envisagenics' pipeline of novel preclinical oncology assets using their cloud-based AI drug discovery platform, SpliceCore®. This collaboration underscores BMS's continued investment in innovative technologies and therapeutics.

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Through strategic partnerships, cutting-edge research, and a commitment to therapeutic advancements, BMS continues to make significant strides in the biopharmaceutical industry.

News

Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

Rhea-AI Summary
Bristol Myers Squibb (BMY) announced two regulatory acceptances for applications for neoadjuvant Opdivo with chemotherapy followed by surgery and adjuvant Opdivo for the perioperative treatment of resectable stage IIA to IIIB non-small cell lung cancer. The U.S. FDA accepted the supplemental Biologics Application (sBLA) and assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 8, 2024. The EMA also validated the type II variation application. The CheckMate -77T trial showed statistically significant improvements in event-free survival, pathologic complete response, and major pathologic response, with a consistent safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
none
-
News

Bristol Myers Squibb Named One of America’s Most JUST Companies by JUST Capital and CNBC

Rhea-AI Summary
Bristol Myers Squibb Company has achieved a top 10 ranking in the Pharmaceutical and Biotech Sector, reflecting the company's strong standing in issues that are important to Americans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
none
-
News

Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Rhea-AI Summary
Bristol Myers Squibb and 2seventy bio, Inc. announced that the FDA will convene a virtual meeting of the Oncologic Drugs Advisory Committee to review data supporting the supplemental Biologics License Application for Abecma for triple-class exposed relapsed or refractory multiple myeloma. The meeting will focus on the secondary endpoint of overall survival from the pivotal Phase 3 KarMMa-3 study. Abecma has recently been approved in Japan and received a positive opinion for marketing authorization from the Committee for Medicinal Products for Human Use of the European Medicines Agency for patients with triple-class exposed relapsed and refractory multiple myeloma after at least two prior therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
none
News

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023

Rhea-AI Summary
Bristol Myers Squibb (BMY) reports fourth quarter revenues of $11.5 billion and full-year revenues of $45.0 billion. GAAP EPS for the full year was $3.86, and non-GAAP EPS was $7.51. The in-line and new product portfolio revenues increased by 9% to $9.8 billion in the fourth quarter and 7% to $37.9 billion for the full year. The company also strengthened its long-term growth profile through multiple transactions, including planned acquisitions of Karuna Therapeutics and RayzeBio, and a strategic collaboration with SystImmune. Additionally, Bristol Myers Squibb advanced its research pipeline, with the U.S. approval of Augtyro and FDA acceptance of sBLAs for Breyanzi in Follicular Lymphoma and Mantle Cell Lymphoma for Priority Review. The company provided 2024 guidance with revenues increasing by low single-digits and a non-GAAP EPS range of $7.10 to $7.40, excluding the impact of pending transactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
earnings
-
News

Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Rhea-AI Summary
Bristol Myers Squibb announces FDA and MHLW acceptance of Breyanzi regulatory applications for treatment of FL and MCL, with Priority Review and PDUFA goal dates in 2024. Clinical trials show high rates of complete responses and no new safety signals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
News

Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial

Rhea-AI Summary
Bristol Myers Squibb announces groundbreaking results from the Phase 3 CheckMate -67T trial, evaluating the subcutaneous formulation of Opdivo in patients with advanced or metastatic clear cell renal cell carcinoma. The trial demonstrates noninferior pharmacokinetics, efficacy, and safety vs. the intravenous formulation, with subcutaneous nivolumab displaying noninferior objective response rate compared to IV Opdivo. The results will be presented at ASCO GU 2024, indicating potential practice-changing implications for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Rhea-AI Summary
Bristol Myers Squibb receives positive CHMP opinion for Abecma in the treatment of relapsed and refractory multiple myeloma. The recommendation is based on the Phase 3 KarMMa-3 study, showing Abecma's superiority over standard regimens, significantly improved progression-free survival, and a well-established safety profile. Approval by the European Commission would expand Abecma's indication, making it the first CAR T cell therapy available in the European Union for patients with triple-class exposed relapsed and refractory multiple myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
none
-
News

Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio

Rhea-AI Summary
Bristol Myers Squibb (BMY) has completed its acquisition of Mirati Therapeutics, Inc., making Mirati a wholly owned subsidiary. The acquisition adds KRAZATI, a commercialized lung cancer medicine, and promising clinical assets to BMS' oncology portfolio. The transaction is expected to be dilutive to BMS' non-GAAP earnings per share by approximately $0.35 per share in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
acquisition
-
News

Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Rhea-AI Summary
Bristol Myers Squibb's Opdivo plus Yervoy demonstrated a 28% reduction in the risk of death vs. sunitinib after eight years for patients with previously untreated advanced or metastatic renal cell carcinoma. The combination showed improved survival and durable responses compared to sunitinib among intermediate- and poor-risk patients. The Phase 3 CheckMate -214 trial results were presented at ASCO GU 2024, showing that Opdivo plus Yervoy maintained efficacy after eight years, with improvements in overall survival, progression-free survival, overall response rate, and duration of response over sunitinib.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none
News

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

Rhea-AI Summary
Bristol Myers Squibb and Exelixis, Inc. announced positive results from the CheckMate -9ER trial, showing that Opdivo in combination with CABOMETYX reduced the risk of death by 23% in the first-line treatment of advanced renal cell carcinoma vs. sunitinib. The combination also demonstrated superior progression-free survival (PFS) and objective response rates (ORR) in patients treated with Opdivo plus CABOMETYX over sunitinib, regardless of risk classification. The four-year follow-up results showed durable and clinically meaningful efficacy, with significant improvements in PFS, OS, ORR, and complete response (CR). No new safety concerns were identified in this follow-up analysis, and the combination regimen also showed benefits in patient subgroups across risk groups. The data will be presented at the ASCO GU 2024 Genitourinary Cancers Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none

FAQ

What is the current stock price of Bristol-Myers Squibb Co. (BMY)?

The current stock price of Bristol-Myers Squibb Co. (BMY) is $57.76 as of December 24, 2024.

What is the market cap of Bristol-Myers Squibb Co. (BMY)?

The market cap of Bristol-Myers Squibb Co. (BMY) is approximately 117.1B.

What is Bristol-Myers Squibb's core business?

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs for various therapeutic areas, including cardiovascular, cancer, and immune disorders.

Where is Bristol-Myers Squibb headquartered?

Bristol-Myers Squibb is headquartered in New York City, USA.

What was Bristol-Myers Squibb's revenue for fiscal 2022?

Bristol-Myers Squibb reported a total revenue of $46.2 billion for fiscal 2022.

What is a significant focus area for Bristol-Myers Squibb?

A significant focus area for Bristol-Myers Squibb is immuno-oncology, where it is a leader in drug development.

How much of Bristol-Myers Squibb's total sales come from the U.S. market?

Approximately 70% of Bristol-Myers Squibb's total sales are derived from the U.S. market.

What recent collaboration did Bristol-Myers Squibb announce with NeoPhore Limited?

On May 22, 2024, Bristol-Myers Squibb joined NeoPhore Limited's Series B extension round to explore novel biology associated with the DNA mismatch repair pathway in cancer.

What is the purpose of Bristol-Myers Squibb's collaboration with I-Mab?

The collaboration with I-Mab focuses on evaluating the combination of givastomig with BMS's nivolumab and chemotherapy for advanced Claudin 18.2-positive gastric and esophageal cancers.

What is SpliceCore®?

SpliceCore® is Envisagenics' cloud-based AI drug discovery platform that integrates machine learning algorithms to identify novel and disease-specific RNA splicing isoforms.

When did Bristol-Myers Squibb participate in Envisagenics' Series B fundraising round?

Bristol-Myers Squibb participated in Envisagenics' Series B fundraising round announced on June 5, 2024.

What is Bristol-Myers Squibb's mission?

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.

Stock BMY logo
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

#108 Ranked by Market Cap
#719 Ranked by Dividends

BMY Stock Data

117.15B
2.03B
0.12%
78.46%
1.27%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
PRINCETON